Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults

Table 5 The association between baseline serum alkaline phosphatase (ALP) and new-onset diabetes, with further adjustment for the use of calcium channel blockers, diuretics and antiplatelet drugs during the treatment period

ALP, IU/L	N	No. of events (%)	Crude model		Adjusted model*
ALP, IU/L	N	No. of events (%)	OR (95% CI)	P value^†	OR (95% CI)	P value^†
Continuous, per SD increment	14,393	1549 (10.8)	1.07 (1.02,1.13)	0.007	1.07 (1.01,1.14)	0.026
Quartiles
Q1 (< 79)	3486	343 (9.8)	1.00 (ref.)		1.00 (ref.)
Q2 (79- < 96)	3623	381 (10.5)	1.08 (0.92,1.26)	0.346	1.09 (0.93,1.28)	0.290
Q3 (96- < 116)	3577	390 (10.9)	1.12 (0.96,1.31)	0.143	1.14 (0.96,1.34)	0.127
Q4 (≥ 116)	3707	435 (11.7)	1.22 (1.05,1.42)	0.010	1.24 (1.05,1.48)	0.013
P for trend			0.009		0.013

ALP serum alkaline phosphatase, CI confidence interval, eGFR estimated glomerular filtration rate, OR odds ratio, SD standard deviations, SBP systolic blood pressure
*Adjusted for age, sex, study center, treatment group, body mass index (BMI), smoking, alcohol drinking, family history of diabetes, SBP, fasting glucose (FG), total cholesterol (TC), triglycerides (TG), eGFR, folate, total homocysteine and the use of antihypertensive drugs at baseline, as well as time-averaged SBP, the use of calcium channel blockers, diuretics and antiplatelet drugs during the treatment period
^†In comparison with the first quartile

ISSN: 1475-2840